Trial periods | T1 Control | T2 100 mg/kg Sangrovit® | T3 500 mg/kg Sangrovit® | T4 1000 mg/kg Sangrovit® | Treatment effect (P=) | ||||
F | CM | F | CM | F | CM | F | CM | ||
D0 - D21 | 1.54 ± 0.50 | 1.50 ± 0.53 | 1.54 ± 0.50 | 1.37 ± 0.49 | 1.55 ± 0.50 | 1.43 ± 0.50 | 1.55 ± 0.52 | 1.48 ± 0.50 | 0.9116 |
D21 - D42 | 1.48 ± 0.50 | 1.57 ± 0.52 | 1.36 ± 0.48 | 1.51 ± 0.53 | 1.52 ± 0.50 | 1.35 ± 0.48 | 1.36 ± 0.48 | 1.52 ± 0.50 | 0.5170 |
D42 - D90 | 1.46 ± 0.51 | 1.52 ± 0.51 | 1.39 ± 0.49 | 1.48 ± 0.50 | 1.38 ± 0.50 | 1.48 ± 0.50 | 1.38 ± 0.49 | 1.48 ± 0.52 | 0.8502 |
D0 - D90 | 1.48 ± 0.51 | 1.53 ± 0.52 | 1.42 ± 0.49 | 1.46 ± 0.50 | 1.45 ± 0.50 | 1.44 ± 0.50 | 1.41 ± 0.50 | 1.49 ± 0.51 | 0.6922 |